亚宝药业集团股份有限公司 关于ZY-A002获得药物临床试验批准通知书的公告

Group 1 - The company has received approval from the National Medical Products Administration for the clinical trial of ZY-A002, which is intended for the treatment of cough variant asthma in children [1][3] - ZY-A002 is classified as a traditional Chinese medicine and is in the granule form, with a registration classification of Category 1.1 [5] - The total sales amount for pediatric cough and phlegm relief traditional Chinese medicine in China is projected to be approximately 6.067 billion RMB in 2024, with public medical market sales accounting for about 4.159 billion RMB and retail pharmacy sales around 1.908 billion RMB [2] Group 2 - The clinical trial application for ZY-A002 was accepted on July 7, 2025, and it is required to conduct Phase III clinical trials before it can be produced and marketed [3] - The company has invested approximately 12.5682 million RMB in the research and development of the ZY-A002 project to date [3]